脑肿瘤手术围术期抗血小板与抗凝管理:一项国际实践调查
本研究向800余名国际神经外科医生发送70题问卷,调查脑肿瘤切除术围术期抗血栓药物管理实践,2021年3月至6月共72名外科医生回复。结果显示抗血小板药物停药时长3至11天、重启1至14天,维生素K拮抗剂术前管理因使用指征而异(P<0.001),直接口服抗凝药(DOAC)则无差异。作者认为实践异质性显著,可能因用药管理误差导致患者伤害。
要点
- 72名国际神经外科医生回复调查,抗血小板停药3至11天、重启1至14天。
- 维生素K拮抗剂术前管理因使用指征而异(P<0.001),DOAC管理无差异。
- 90%受访者术后5天内启动肝素类产品,90%在14天内重启DOAC。
核心结论
- 受访者在脑肿瘤切除术围术期抗血小板与抗凝药物管理上表现出显著异质性,这种实践异质性可能因用药管理误差而造成患者伤害。
研究设计与样本
- 向神经外科研究邮件列表(Neurosurgery Research Listserv)中800余名国际神经外科会员发送70题问卷,评估围术期血栓预防、抗血小板药物和抗凝药物的个体实践,调查于2021年3月至2021年6月通过电子邮件邀请发送。
主要发现
- 共72名外科医生回复问卷。
- 比较轴内与轴外肿瘤切除术,术前或术后药物管理无差异。
- 抗血小板药物停药时长在3至11天之间变化,重启时长在1至14天之间变化。
- 维生素K拮抗剂术前管理因使用指征而异(P<0.001),DOAC管理则无差异。
- 受访者中90%在手术后5天内启动肝素类产品,同样比例的受访者在14天内重启DOAC。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Perioperative management of antithrombotic therapy is a necessary preprocedural consideration for patients prescribed direct oral anticoagulants (DOACs), vitamin K antagonists, or antiplatelet medications. There is a lack of evidence-based guidelines to help inform decision-making in managing antiplatelet and anticoagulation medications in the perioperative period around brain tumor resection. The objective of this study was to provide an example of the heterogeneity in practice and raise awareness for the need to create standardized guidelines for managing these medications. METHODS: A survey was sent to a list of over 800 international neurosurgeons who are members of the Neurosurgery Research Listserv. The survey comprised 70 questions assessing individual practices for managing thromboprophylaxis, antiplatelet medications, and anticoagulation in the perioperative period. The survey was sent via e-mail invitation between March 2021 and June 2021. RESULTS: A total of 72 surgeons responded to the survey. There was no difference in medication management preoperatively or postoperatively when comparing intra- and extra-axial tumor resections. Cessation of antiplatelet medications varied between 3 and 11 days while restart varied between 1 and 14 days. Preoperative management of vitamin K antagonists varied between indication for use (P < 0.001) while DOAC management did not. In our group of respondents, 90% started heparin products within 5 days of surgery, while the same fraction restarted DOAC within 14 days. CONCLUSIONS: Respondents demonstrated significant heterogeneity in their perioperative management of antiplatelet and anticoagulation medication in brain tumor resection. This may lead to an unacceptable level of heterogeneity in practice that has the potential to cause patient harm due to errors in medication management.
引用
- Bailey D, Wilding H, Ganesalingam N, et al. Perioperative Management of Antiplatelet and Anticoagulation in Brain Tumor Surgery: A Survey of International Practices. World Neurosurg. 2024. PMID: 39038643. doi:10.1016/j.wneu.2024.07.111
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。